Literature DB >> 28613220

OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.

Ana R Santos1,2, Miguel  Costa1, Christian Schwartz1, Dalila Alves1, João Figueira1,3,4, Rufino Silva1,3,4, Jose G Cunha-Vaz1,4.   

Abstract

PURPOSE: To identify baseline optical coherence tomography morphologic characteristics predicting the visual response to anti-vascular endothelial growth factor therapy in diabetic macular edema.
METHODS: Sixty-seven patients with diabetic macular edema completed a prospective, observational study (NCT01947881-CHARTRES). All patients received monthly intravitreal injections of Lucentis for 3 months followed by PRN treatment and underwent best-corrected visual acuity measurements and spectral domain optical coherence tomography at Baseline, Months 1, 2, 3, and 6. Visual treatment response was characterized as good (≥10 letters), moderate (5-10 letters), and poor (<5 or letters loss). Spectral domain optical coherence tomography images were graded before and after treatment by a certified Reading Center.
RESULTS: One month after loading dose, 26 patients (38.80%) were identified as good responders, 19 (28.35%) as Moderate and 22 (32.83%) as poor responders. There were no significant best-corrected visual acuity and central retinal thickness differences at baseline (P = 0.176; P = 0.573, respectively). Ellipsoid zone disruption and disorganization of retinal inner layers were good predictors for treatment response, representing a significant risk for poor visual recovery to anti-vascular endothelial growth factor therapy (odds ratio = 10.96; P < 0.001 for ellipsoid zone disruption and odds ratio = 7.05; P = 0.034 for disorganization of retinal inner layers).
CONCLUSION: Damage of ellipsoid zone, higher values of disorganization of retinal inner layers, and central retinal thickness decrease are good predictors of best-corrected visual acuity response to anti-vascular endothelial growth factor therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28613220     DOI: 10.1097/IAE.0000000000001687

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  11 in total

1.  Response to: Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema.

Authors:  António Campos; Elisa J Campos; Anália do Carmo; Rufino Silva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-09-06       Impact factor: 3.117

2.  Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.

Authors:  Amy S Babiuch; Michael Han; Felipe F Conti; Karen Wai; Fabiana Q Silva; Rishi P Singh
Journal:  JAMA Ophthalmol       Date:  2019-01-01       Impact factor: 7.389

Review 3.  Profile of non-responder and late responder patients treated for diabetic macular edema: systemic and ocular factors.

Authors:  Mariacristina Parravano; Eliana Costanzo; Giuseppe Querques
Journal:  Acta Diabetol       Date:  2020-02-29       Impact factor: 4.280

4.  Microperimetry and mfERG as functional measurements in diabetic macular oedema undergoing intravitreal ranibizumab treatment.

Authors:  Ana Rita Santos; Miguel Raimundo; Dalila Alves; Marta Lopes; Sérgio Pestana; João Figueira; José Cunha-Vaz; Rufino Silva
Journal:  Eye (Lond)       Date:  2020-07-02       Impact factor: 3.775

5.  Relationship Between Final Visual Acuity and Optical Coherence Tomography Findings in Patients with Diabetic Macular Edema Undergoing Anti-VEGF Therapy

Authors:  Seher Eraslan; Özlem Yıldırım; Özer Dursun; Erdem Dinç; Gülhan Orekici Temel
Journal:  Turk J Ophthalmol       Date:  2020-06-27

6.  Macular Features on Spectral-Domain Optical Coherence Tomography Imaging Associated With Visual Acuity in Coats' Disease.

Authors:  Sally S Ong; Prithvi Mruthyunjaya; Sandra Stinnett; Lejla Vajzovic; Cynthia A Toth
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-06-01       Impact factor: 4.799

7.  Effect of ripasudil on diabetic macular edema.

Authors:  Yoshiro Minami; Young-Seok Song; Akihiro Ishibazawa; Tsuneaki Omae; Tomoko Ro-Mase; Satoshi Ishiko; Akitoshi Yoshida
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

8.  GRAding of functional and anatomical response to DExamethasone implant in patients with Diabetic Macular Edema: GRADE-DME Study.

Authors:  Patricio J Rodríguez-Valdés; Matus Rehak; Matias Iglicki; Catharina Busch; Dinah Zur; Anna Sala-Puigdollers; Samantha Fraser-Bell; Marco Lupidi; Jay Chhablani; Zafer Cebeci; Inês Laíns; Voraporn Chaikitmongkol; Adrian T Fung; Mali Okada; Jan Darius Unterlauft; Lital Smadar; Anat Loewenstein
Journal:  Sci Rep       Date:  2021-02-26       Impact factor: 4.379

9.  Evaluation of markers of outcome in real-world treatment of diabetic macular edema.

Authors:  António Campos; Elisa J Campos; Anália do Carmo; Francisco Caramelo; João Martins; João P Sousa; António Francisco Ambrósio; Rufino Silva
Journal:  Eye Vis (Lond)       Date:  2018-10-11

10.  Defining Cystoid Macular Degeneration in Diabetic Macular Edema: An OCT-Based Single-center Study

Authors:  Gökçen Yalçın; Şengül Özdek; Fatma Nur Baran Aksakal
Journal:  Turk J Ophthalmol       Date:  2019-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.